secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2026-01-30T23:59:59+00:00
Accession:  0001193125-26-031987
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech explores strategic alternatives, cuts workforce, CMO departs, hires Raymond James
--------------------------------------------------------------------------------

- Retained Raymond James as exclusive financial advisor to assist in exploration of strategic alternatives.
- Board approved restructuring plan; expects $2.4M-$2.6M in one-time charges in Q1 2026.
- Chief Medical Officer Qasim Ahmad's employment will end effective Feb 15, 2026.
- Company implementing significant global workforce reduction to reduce operating expenses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312526031987/0001193125-26-031987-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312526031987/d13704d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-031987

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer